Clinical Trial Update: A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of CDX-3379 with cetuximab in advanced head and neck squamous cell carcinoma was terminated with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CDX-3379 (CDX-3379)
• Cetuximab (cetuximab)

Snippet

Sponsor: Celldex Therapeutics | Conditions: Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2023-04-03